נקטין תרפיוטיקס בע"מ

חברה המפתחת תרופות אימונואונקולוגיות על בסיס נוגדני IMMUNE CHECKPOINT INHIBITORS ו- ANTIBODY DRUG CONJUGATES

Nectin Therapeutics is a clinical stage biotechnology company devoted to transforming the lives of cancer patients by leveraging unique insights into nectin pathways to develop the next generation of immune oncology (IO) therapies. The company's differentiated therapies have the potential to set new standards for efficacy and patient response rates across various difficult-to-treat cancers. Nectin's technology addresses major escape mechanisms of current IO therapies through a diverse pipeline of novel monoclonal antibodies and antibody drug conjugates (ADCs). It has a world-class scientific and management team with deep experience in oncology drug development and successful track records in building biotechnology companies and developing innovative therapies.

Patients with advanced and metastatic solid tumors, doctors and clinics that treat cancer patients in need.

Fabian Tenenbaum - CEO